



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

Last Trade:	23.50
Trade Time:	4:00 PM ET Aug 15, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	12.35 - 28.30
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 3, 2017*

[Revance Releases Second Quarter 2017 Results](#)

*Aug 2, 2017*

[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)

*Aug 1, 2017*

[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)

*Jul 24, 2017*

[Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017](#)

*Jun 15, 2017*

[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Feb 28, 2017*

[Annual Report \(10-K\)](#)

*Mar 24, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 4, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 4, 2016*

[Quarterly Report \(10-Q\)](#)